BRAF and melanoma: Our findings raise the hypothesis that combining bevacizumab with adjuvant immune checkpoint inhibitors may benefit high-risk BRAF mutant melanoma patients, who in our study had a poorer prognosis than patients with tumours lacking the mutation.